Charles River Laboratories Long-Term Investments 2010-2024 | CRL

Charles River Laboratories long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • Charles River Laboratories long-term investments for the quarter ending June 30, 2024 were $0.232B, a 22.79% decline year-over-year.
  • Charles River Laboratories long-term investments for 2023 were $0.244B, a 21.76% decline from 2022.
  • Charles River Laboratories long-term investments for 2022 were $0.312B, a 54.75% increase from 2021.
  • Charles River Laboratories long-term investments for 2021 were $0.201B, a INF% increase from 2020.
Charles River Laboratories Annual Long-Term Investments
(Millions of US $)
2023 $244
2022 $312
2021 $201
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Charles River Laboratories Quarterly Long-Term Investments
(Millions of US $)
2024-06-30 $232
2024-03-31 $244
2023-12-31 $244
2023-09-30 $302
2023-06-30 $300
2023-03-31 $294
2022-12-31 $312
2022-09-30
2022-06-30
2022-03-31
2021-12-31 $201
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Services $11.285B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $98.658B 12.24
Cencora (COR) United States $49.082B 18.10
DiDi Global (DIDIY) China $23.427B 0.00
ICON (ICLR) Ireland $17.504B 15.59
Natera (NTRA) United States $16.570B 0.00
Viatris (VTRS) United States $15.624B 4.81
Avantor (AVTR) United States $15.178B 22.75
Revvity (RVTY) United States $14.682B 25.50
BioMerieux (BMXMF) France $13.087B 0.00
CochLear (CHEOY) Australia $12.998B 0.00
Solventum (SOLV) United States $12.357B 0.00
Doximity (DOCS) United States $11.372B 67.31
Medpace Holdings (MEDP) United States $11.301B 31.84
HealthEquity (HQY) United States $8.756B 47.52
Sonic Healthcare (SKHHY) Australia $8.590B 0.00
Bausch + Lomb (BLCO) Canada $7.202B 33.53
Life Times (LTH) United States $5.139B 34.01
Sotera Health (SHC) United States $4.509B 24.12
Organon (OGN) United States $4.144B 4.18
Surgery Partners (SGRY) United States $3.996B 44.27
BrightSpring Health Services (BTSG) United States $3.489B 74.22
PACS (PACS) United States $3.347B 0.00
Alignment Healthcare (ALHC) United States $2.580B 0.00
Concentras Parent (CON) United States $2.505B 0.00
Ardent Health Partners (ARDT) United States $2.471B 0.00
Premier (PINC) United States $2.314B 11.55
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $2.016B 0.00
GoodRx Holdings (GDRX) United States $1.856B 48.90
Teladoc Health (TDOC) United States $1.689B 0.00
Progyny (PGNY) United States $1.540B 27.08
Pediatrix Medical (MD) United States $1.371B 13.41
Establishment Labs Holdings (ESTA) $1.266B 0.00
CareDx (CDNA) United States $1.252B 0.00
AMN Healthcare Services Inc (AMN) United States $1.058B 7.16
Embecta (EMBC) United States $0.910B 6.07
Agilon Health (AGL) United States $0.890B 0.00
InnovAge Holding (INNV) United States $0.809B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.723B 0.00
Auna S.A (AUNA) Luxembourg $0.516B 0.00
Sonida Senior Living (SNDA) United States $0.459B 0.00
DocGo (DCGO) United States $0.411B 15.46
Enhabit (EHAB) United States $0.403B 34.83
COMPASS Pathways (CMPS) United Kingdom $0.363B 0.00
LifeMD (LFMD) United States $0.308B 0.00
Sera Prognostics (SERA) United States $0.248B 0.00
ModivCare (MODV) United States $0.231B 12.54
Beauty Health (SKIN) United States $0.218B 0.00
Biodesix (BDSX) United States $0.205B 0.00
Nutex Health (NUTX) United States $0.152B 0.00
MultiPlan (MPLN) United States $0.137B 0.00
Ascend Wellness Holdings (AAWH) United States $0.107B 0.00
So-Young (SY) China $0.088B 21.28
Singular Genomics Systems (OMIC) United States $0.057B 0.00
Harvard Apparatus Regenerative Technology (HRGN) United States $0.054B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.042B 1.10
Co-Diagnostics (CODX) United States $0.038B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.028B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.020B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.008B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00